

Specific Comments to Authors:

1 Title. Does the title reflect the main subject/hypothesis of the manuscript? YES. I would add "meta-analysis" in the title.

Reply: The "meta-analysis" were added.

2 Abstract. Does the abstract summarize and reflect the work described in the manuscript? YES

Reply: OK.

3 Key words. Do the key words reflect the focus of the manuscript? YES

Reply: OK.

4 Background. Does the manuscript adequately describe the background, present status and significance of the study? YES

Reply: OK.

5 Methods. Does the manuscript describe methods (e.g., experiments, data analysis, surveys, and clinical trials, etc.) in adequate detail? YES

Reply: OK.

6 Results. Are the research objectives achieved by the experiments used in this study? YES What are the contributions that the study has made for research progress in this field? The authors performed a systematic review base on 12 RCTs on the clinical benefit of COX2 inhibitors combined with adjuvant chemotherapy in the treatment of advanced NSCLC patients. This metaanalysis demonstrated that in terms of ORR for patients received adjuvant chemotherapy of advanced NSCLC, COX-2 inhibitors improved the ORR and have no improvement on prolonged mortality. However, particularly with first-line chemotherapy, the COX-2 could enhance both the ORR and improved the 1-year SR. Concerning toxicity, celecoxib plus chemotherapy resulted in a higher incidence of hematologic toxicities. Meanwhile, the rofecoxib may augment the risk of cardiovascular events.

Reply: OK.

7 Discussion. Does the manuscript interpret the findings adequately and appropriately, highlighting the key points concisely, clearly and logically? Are the findings and their applicability/relevance to the literature stated in a clear and definite manner? Is the discussion accurate and does it discuss the paper's scientific significance and/or relevance to clinical practice sufficiently? YES. In my opinion all these aspects are fulfilled.

Reply: OK.

8 Illustrations and tables. Are the figures, diagrams and tables sufficient, good quality and appropriately illustrative of the paper contents? Do figures require labeling with arrows, asterisks etc., better legends? All the figures are clear.

Reply: OK.

9 Biostatistics. Does the manuscript meet the requirements of biostatistics?

Reply: OK.

10 Units. Does the manuscript meet the requirements of use of SI units?

Reply: OK.

11 References. Does the manuscript cite appropriately the latest, important and authoritative references in the introduction and discussion sections? Does the author self-cite, omit, incorrectly cite and/or over-cite references?

Reply: OK.

12 Quality of manuscript organization and presentation. Is the manuscript well, concisely and coherently organized and presented? Is the style, language and grammar accurate and appropriate?

Reply: OK.

13 Research methods and reporting. Authors should have prepared their manuscripts according to manuscript type and the appropriate categories, as follows: (1) CARE Checklist (2013) - Case report; (2) CONSORT 2010 Statement - Clinical Trials study, Prospective study, Randomized Controlled trial, Randomized Clinical trial; (3) PRISMA 2009 Checklist - Evidence-Based Medicine, Systematic review, Meta-Analysis; (4) STROBE Statement - Case Control study, Observational study, Retrospective Cohort study; and (5) The ARRIVE Guidelines - Basic study. Did the author prepare the manuscript according to the appropriate research methods and reporting?

Reply: OK. The PRISMA 2009 Checklist will be added.

14 Ethics statements. For all manuscripts involving human studies and/or animal experiments, author(s) must submit the related formal ethics documents that were reviewed and approved by their local ethical review committee. Did the manuscript meet the requirements of ethics?

Reply: OK. There is no need for ethics.

EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

(1) Science editor:

1 Scientific quality: The manuscript describes a systematic review of the clinical benefit of cyclooxygenase-2 inhibitors in the adjuvant chemotherapy of advanced NSCLC. The topic is within the scope of the WJCC. (1) Classification: Grade A; (2) Summary of the Peer-Review Report: The authors performed a systematic review base on 12 RCTs on the clinical benefit of COX2 inhibitors combined with adjuvant chemotherapy in the treatment of advanced NSCLC patients. This meta-analysis demonstrated that in terms of ORR for patients received adjuvant chemotherapy of advanced NSCLC, COX-2 inhibitors improved the ORR and has no improvement on prolonged mortality. The questions raised by the reviewers should be answered; and (3) Format: There are 3 tables and 9 figures. A total of 40 references are cited, including 2 references published in the last 3 years. There are no self-citations.

Reply: OK.

2 Language evaluation: Classification: Grade A. A language editing certificate issued by AJE was provided.

Reply: OK.

3 Academic norms and rules: The authors provided the Biostatistics Review Certificate, the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement. No academic misconduct was found in the CrossCheck detection and Bing search.

Reply: OK.

4 Supplementary comments: This is an unsolicited manuscript. The study was supported by Sanming Project of Medicine in Shenzhen. The topic has not previously been published in the WJCC.

Reply: OK.

5 Issues raised: (1) The authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s); (2) The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor; (3) PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout; and (4) The "Article Highlights" section is missing. Please add the "Article Highlights" section at the end of the main text.

Reply: OK.

(1) The approved grant application form(s) or funding agency copy had been uploaded.

深圳市卫生健康委员会文件

深卫健科教〔2019〕32号

市卫生健康委关于确定2019年度引进高层次 医学团队预立项项目的通知

委属各单位：

根据《深圳市人民政府关于印发“医疗卫生三名工程”政策措施的通知》（深府〔2014〕99号）和《2019年度深圳市引进高层次医学团队申报工作方案》（深卫健科教〔2019〕9号），我委组织开展了深圳市2019年度引进高层次医学团队评审认定工作。根据评审认定结果，结合我市卫生健康服务需求、医学学科发展状况等，我委确定了2019年度引进高层次医学团队预立项项目（具体名单见附件1），现予公布。


所有预立项项目的依托单位，须与引进团队沟通、细化合

序号	引进单位	引进团队	预立项类别	拟资助专项经费总额(万元)
13	香港大学深圳医院	香港大学袁国勇院士感染性疾病团队	A	1500
14	香港大学深圳医院	英国伦敦帝国学院 Dudley Pennell 院士心血管影像精准医学团队	B	1000
15	深圳市急救中心	北京大学公共卫生学院郑志杰教授急救医疗体系建设团队	B	1000
16	深圳市第三人民医院	中国医学科学院王辰院士结核病综合立体防治体系建设创新团队	A	1500
17	深圳大学总医院	空军军医大学武胜昔教授脊髓损伤防治与功能重建研究团队	B	1000
18	深圳大学总医院	天津大学灾难医学研究院郑静晨院士急救与灾难医学团队	A	1500
19	深圳大学慢性病防治中心	中国医学科学院肿瘤医院陈万青教授癌症预防团队	B	1000
20	南方医科大学深圳医院	南方医科大学侯金林教授慢性肝病精准防治团队	B	1000

(2) The graphics drawn by R software are not saved as PowerPoint format. Therefore, PDF format is provided as the format of figures.

If the editorial department also need PowerPoint Format, we will use other software to draw related graphics to provide journal.

Thanks for your work.



(3) The PubMed numbers and DOI citation numbers had been uploaded.

References 9,10,11,40 only found PMID and no DOI. Reference 20 is a book, so there is no PMID and DOI. References 28,29,30,31 are included Chinese studies, so there are no PMID and DOI.

(4) The “Article Highlights” section at the end of the main text had been added.

6 Re-Review: Required.

Reply: OK.

7 Recommendation: Conditional acceptance.

Reply: OK.